Phase I trial of intermittent administration of sorafenib (BAY 43-9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML)

被引：0
|
作者：
Quintas-Cardama, A.
Kantarjian, H.
Andreef, M.
Faderl, S.
Wright, J.
Zhang, W.
Konopleva, M.
Verstovsek, S.
Borthakur, G.
Cortes, J.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] NCI, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7018
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors
    Richly, H
    Henning, BF
    Kupsch, P
    Passarge, K
    Grubert, M
    Hilger, RA
    Christensen, O
    Brendel, E
    Schwartz, B
    Ludwig, M
    Flashar, C
    Voigtmann, R
    Scheulen, ME
    Seeber, S
    Strumberg, D
    ANNALS OF ONCOLOGY, 2006, 17 (05) : 866 - 873
  • [2] Phase I trial of sorafenib (BAY 43-9006) combined with dacarbazine (DTIC) in patients with metastatic melanoma
    Eisen, T.
    Ahmad, T.
    Marais, R.
    Gibbens, I.
    James, M.
    Affolter, A.
    Chao, D.
    Bergamini, L.
    Schwartz, B.
    Gore, M. E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 349 - 349
  • [3] Sorafenib (BAY 43-9006) directly targets FLT3-ITD in acute myelogenous leukemia.
    Zhang, Weiguo
    Konopleva, Marina
    Shi, Yue-Xi
    Harris, David
    Small, Donald
    Ling, Xiaoyang
    Estrov, Zeev
    Cortes, Jorge
    Andreeff, Michael
    BLOOD, 2006, 108 (11) : 79A - 80A
  • [4] Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors
    Richly, H
    Kupsch, P
    Passarge, K
    Grubert, M
    Hilger, RA
    Haase, CG
    Schwartz, B
    Scheulen, ME
    Seeber, S
    Strumberg, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 207S - 207S
  • [5] Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors
    Kupsch, P
    Passarge, K
    Richly, H
    Wiesemann, K
    Hilger, RA
    Haase, CG
    Schwartz, B
    Scheulen, ME
    Seeber, S
    Strumberg, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 209S - 209S
  • [6] Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients.
    Eisen, T
    Ahmad, T
    Gore, ME
    Marais, R
    Gibbens, I
    James, MG
    Schwartz, B
    Bergamini, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 712S - 712S
  • [7] A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401)
    Nabors, L. B.
    Rosenfeld, M.
    Chamberlain, M.
    Phuphanich, S.
    Batchelor, T.
    Supko, J.
    Desideri, S.
    Xiaobu, Y.
    Wright, J.
    Grossman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma
    Uldrick, Thomas S.
    Goncalves, Priscila H.
    Wyvill, Kathleen M.
    Peer, Cody J.
    Bernstein, Wendy
    Aleman, Karen
    Polizzotto, Mark N.
    Venzon, David
    Steinberg, Seth M.
    Marshall, Vickie
    Whitby, Denise
    Little, Richard F.
    Wright, John J.
    Rudek, Michelle A.
    Figg, William D.
    Yarchoan, Robert
    ONCOLOGIST, 2017, 22 (05): : 505 - +
  • [9] Phase II trial of sorafenib (bay 43-9006) in malignant mesothelioma: CALGB 30307
    Janne, Pasi A.
    Wang, Xiaofei F.
    Krug, Lee M.
    Hodgson, Lydia
    Vokes, Everett E.
    Kindler, Hedy L.
    ANNALS OF ONCOLOGY, 2006, 17 : 216 - 217
  • [10] Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma:: CALGB 30307
    Janne, P. A.
    Wang, X. F.
    Krug, L. M.
    Hodgson, L.
    Vokes, E. E.
    Kindler, H. L.
    LUNG CANCER, 2006, 54 : S51 - S52
12345